Literature DB >> 22571373

Biosecurity measures in 48 isolation facilities managing highly infectious diseases.

Vincenzo Puro1, Francesco M Fusco, Stefan Schilling, Gail Thomson, Giuseppina De Iaco, Philippe Brouqui, Helena C Maltezou, Barbara Bannister, René Gottschalk, Hans-Rheinhard Brodt, Giuseppe Ippolito.   

Abstract

Biosecurity measures are traditionally applied to laboratories, but they may also be usefully applied in highly specialized clinical settings, such as the isolation facilities for the management of patients with highly infectious diseases (eg, viral hemorrhagic fevers, SARS, smallpox, potentially severe pandemic flu, and MDR- and XDR-tuberculosis). In 2009 the European Network for Highly Infectious Diseases conducted a survey in 48 isolation facilities in 16 European countries to determine biosecurity measures for access control to the facility. Security personnel are present in 39 facilities (81%). In 35 facilities (73%), entrance to the isolation area is restricted; control methods include electronic keys, a PIN system, closed-circuit TV, and guards at the doors. In 25 facilities (52%), identification and registration of all staff entering and exiting the isolation area are required. Access control is used in most surveyed centers, but specific lacks exist in some facilities. Further data are needed to assess other biosecurity aspects, such as the security measures during the transportation of potentially contaminated materials and measures to address the risk of an "insider attack."

Entities:  

Mesh:

Year:  2012        PMID: 22571373      PMCID: PMC3374382          DOI: 10.1089/bsp.2011.0098

Source DB:  PubMed          Journal:  Biosecur Bioterror        ISSN: 1538-7135


  12 in total

Review 1.  Biosafety and biosecurity measures: management of biosafety level 3 facilities.

Authors:  Adel N Zaki
Journal:  Int J Antimicrob Agents       Date:  2010-08-30       Impact factor: 5.283

Review 2.  EuroNHID checklists for the assessment of high-level isolation units and referral centres for highly infectious diseases: results from the pilot phase of a European survey.

Authors:  F M Fusco; S Schilling; V Puro; H-R Brodt; P Follin; B Jarhall; B Bannister; H C Maltezou; G Thomson; P Brouqui; G Ippolito
Journal:  Clin Microbiol Infect       Date:  2009-05-28       Impact factor: 8.067

3.  Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany.

Authors:  Stephan Günther; Heinz Feldmann; Thomas W Geisbert; Lisa E Hensley; Pierre E Rollin; Stuart T Nichol; Ute Ströher; Harvey Artsob; Clarence J Peters; Thomas G Ksiazek; Stephan Becker; Jan ter Meulen; Stephan Olschläger; Jonas Schmidt-Chanasit; Hinrich Sudeck; Gerd D Burchard; Stefan Schmiedel
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

4.  Designing a biocontainment unit to care for patients with serious communicable diseases: a consensus statement.

Authors:  Philip W Smith; Arthur O Anderson; George W Christopher; Theodore J Cieslak; G J Devreede; Glen A Fosdick; Carl B Greiner; John M Hauser; Steven H Hinrichs; Kermit D Huebner; Peter C Iwen; Dawn R Jourdan; Mark G Kortepeter; V Paul Landon; Patricia A Lenaghan; Robert E Leopold; Leroy A Marklund; James W Martin; Sharon J Medcalf; Robert J Mussack; Randall H Neal; Bruce S Ribner; Jonathan Y Richmond; Chuck Rogge; Leo A Daly; Gary A Roselle; Mark E Rupp; Anthony R Sambol; Joann E Schaefer; John Sibley; Andrew J Streifel; Susanna G Von Essen; Kelly L Warfield
Journal:  Biosecur Bioterror       Date:  2006

5.  Misrepresentation of health risks by mass media.

Authors:  Larisa J Bomlitz; Mayer Brezis
Journal:  J Public Health (Oxf)       Date:  2008-02-15       Impact factor: 2.341

6.  European perspective of 2-person rule for biosafety level 4 laboratories.

Authors:  Giuseppe Ippolito; Carla Nisii; Antonino Di Caro; David Brown; Robin Gopal; Roger Hewson; Graham Lloyd; Stephan Gunther; Markus Eickmann; Ali Mirazimi; Tuija Koivula; Marie-Claude Georges Courbot; Hervé Raoul; Maria R Capobianchi
Journal:  Emerg Infect Dis       Date:  2009-11       Impact factor: 6.883

7.  Managing potential laboratory exposure to ebola virus by using a patient biocontainment care unit.

Authors:  Mark G Kortepeter; James W Martin; Janice M Rusnak; Theodore J Cieslak; Kelly L Warfield; Edwin L Anderson; Manmohan V Ranadive
Journal:  Emerg Infect Dis       Date:  2008-06       Impact factor: 6.883

8.  Potential impact of a 2-person security rule on BioSafety Level 4 laboratory workers.

Authors:  James W LeDuc; Kevin Anderson; Marshall E Bloom; Ricardo Carrion; Heinz Feldmann; J Patrick Fitch; Joan B Geisbert; Thomas W Geisbert; Michael R Holbrook; Peter B Jahrling; Thomas G Ksiazek
Journal:  Emerg Infect Dis       Date:  2009-07       Impact factor: 6.883

Review 9.  Framework for the design and operation of high-level isolation units: consensus of the European Network of Infectious Diseases.

Authors:  Barbara Bannister; Vincenzo Puro; Francesco Maria Fusco; Julia Heptonstall; Giuseppe Ippolito
Journal:  Lancet Infect Dis       Date:  2009-01       Impact factor: 25.071

10.  Infection control in the management of highly pathogenic infectious diseases: consensus of the European Network of Infectious Disease.

Authors:  Philippe Brouqui; Vincenzo Puro; Francesco M Fusco; Barbara Bannister; Stephan Schilling; Per Follin; René Gottschalk; Robert Hemmer; Helena C Maltezou; Kristi Ott; Renaat Peleman; Christian Perronne; Gerard Sheehan; Heli Siikamäki; Peter Skinhoj; Giuseppe Ippolito
Journal:  Lancet Infect Dis       Date:  2009-05       Impact factor: 25.071

View more
  1 in total

Review 1.  The Culture of Biosafety, Biosecurity, and Responsible Conduct in the Life Sciences: A Comprehensive Literature Review.

Authors:  Dana Perkins; Kathleen Danskin; A Elise Rowe; Alicia A Livinski
Journal:  Appl Biosaf       Date:  2019-03-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.